Incidental Findings and Next-Generation Genomic Research

Benjamin E. Berkman, JD, MPH
Office of the Clinical Director, NHGRI
and
Department of Bioethics, Clinical Center
National Institutes of Health
Disclaimer

- The following presentation does not reflect the official views of the NHGRI, NIH, or DHHS.
Roadmap

- Background: next-generation sequencing
- Incidental findings in genetic research
- Case discussion highlighting unresolved ethical controversies and questions
Glossary of Terms/Acronyms

- GWAS = genome-wide association studies
- SNP = single nucleotide polymorphism
- dbGaP = database of Genotypes and Phenotypes
- WES = whole exome sequencing
- WGS = whole genome sequencing
- NGS = next generation sequencing
- IF = incidental findings
Definition

An incidental result is:

“[A] finding concerning an individual research participant that has potential health or reproductive importance and is discovered in the course of conducting research but is beyond the aims of the study”

Background: Next-generation sequencing
Advancing Sequencing Capacity

Cost per Genome

Next-Gen Sequencing

Moore's Law
En Route to Routine Whole-Genome Sequencing

Targeted Genetic Research

Whole ‘Exome’

Then

Whole Genome

Now

Soon!

Time
The Future of Genomic Medicine

Incidental Findings in Genetic Research
General Argument

- WES/WGS does not raise novel ethical concerns, but...

- ...it will significantly magnify and make more concrete many of the risks that have been relatively theoretical to this point...

- ...challenging some basic assumptions about how to handle incidental findings in genetic research

(Tabor, Berkman, Hull, et. al., 2011, AJMG, How Exome and Whole Genome Sequencing Challenge the Framework of Human Genetic Research)
A new way of thinking about returning incidental findings?

- **Current assumption #1**
  - Traditional genetic research will produce very few clinically significant incidental findings

- **Revised assumption #1**
  - It is no longer a question of whether or not clinically relevant results will be found in any research participant, but rather how many results will be identified in each participant.
Looking for Incidental findings in a Whole Genome

- **WGS** was performed on 2 monozygotic twins
- **44,270** variants detected initially
  - Exclude bad data
  - Exclude known non-pathogenic variants and variants in untranslated regions, noncoding regions, synonymous changes
- **1,407** possibly pathogenic variants
  - Excluding clearly false positive data
- **430** variants
Incidental Findings and WGS

- Looking at raw data, cross reference each of the 430 variants with existing databases and published literature to determine which variants occur in genes connected to any human disease or condition.

- Results
  - 8 likely pathogenic variants that definitely need to be confirmed;
  - 30 potentially pathogenic variants that might be clinically relevant and will be discussed by a group of clinicians, medical geneticists, genetic counselors and ethicists to determine whether they meet the protocol’s threshold reporting criteria in our protocol.
A new way of thinking about returning incidental findings?

- **Current assumption #2**
  - A clear distinction exists between so-called “incidental” findings and findings that are explicitly related to the original study hypotheses or disease focus.

- **Revised assumption #2**
  - For experimental approaches based on WES/WGS, this distinction between incidental and non-incidental findings will become less meaningful.
A new way of thinking about returning incidental findings?

- **Current assumption #3**
  - Don’t look, don’t tell:
    - “Researchers generally have no obligation to act as clinicians and affirmatively search for IFs” (Wolf et al.)

- **Revised assumption #3**
  - With WGS technology, the act of “looking” for all possible results becomes much more practical and indeed is a fundamental component of the analytical approach
The Problem with Technological Advances

Is Next-Gen Sequence Analysis giving you a headache?

- It's too complex...
- There's too much data...
- Can't visualize it...
- Don't know what it means...
From the Mouths of IRBs…

- There is more than one ethically-defensible approach to WES research

- “It’s much more case-by-case. What are the protocols? Who are the people? What’s the relationship between the investigators and the people whom they’re studying?”
From the Mouths of IRBs...

- IRBs are still figuring out how to review WES protocols

- “We certainly don’t have a policy, and I don’t know that we really have come to a firm conclusion. I mean, it gets discussed every time, and there’s disagreement every time.”
think we’ve gone through several different discussions in our IRB for each specific protocol, but I think we are still at the stage where we hear from investigators what their approach is, and then we decide at the meeting if that sounds reasonable.”
## Three Emerging Models

<table>
<thead>
<tr>
<th>Design</th>
<th>(Re)consent Covers:</th>
</tr>
</thead>
</table>
| No incidental findings to be disclosed      | • **Nature and scope of analysis**  
• **Datasharing plans**  
• That results will NOT be disclosed  
  • even though they might be generated |
| Limited incidental findings to be disclosed | • **Nature and scope of analysis**  
• **Datasharing plans**  
• That results might be disclosed under carefully defined circumstances  
  • Though unlikely |
| More robust plans for disclosure of findings | • **Nature and scope of analysis**  
• **Datasharing plans**  
• That results might be disclosed under carefully defined circumstances  
  • How preferences will be solicited  
  • Any “mandatory disclosure” provisions |
Guidelines and Frameworks

- NHLBI (2004)
- NHLBI (2009)
- Result-evaluation approach (Ravitsky and Wilfond, 2006)
- Net-benefit approach (Wolf, et al., 2008)
- Ancillary care framework (e.g., Beskow and Burke, 2010)
- Tiered-consent model (Rothstein, 2006)
- Etc.
Unresolved Ethical Controversies and Questions
Arguments for returning results

- **Beneficence:** the idea that researchers should have the welfare of the research participant as a goal.

- **Respect for autonomy:** the recognition that all individuals have the right to make their own decisions.

- **Duty to warn:** obligation to warn participants if they are in significant, imminent danger.

- **Right to know:** research participants have an inherent right to obtain genetic information about themselves.
Arguments for returning results

- **Reciprocity**: the idea that investigators owe participants something in exchange for their contribution to the research endeavor.

- **Autonomy**: Genetic information is important and when incorporated into decision-making can enhance autonomy.

- **Doctor-Patient relationship**: participants should be treated like patients, and clinicians would disclose these results to their patients.

- **Professional responsibility** to inform their subjects.
Arguments for Returning Results

- **Legal liability**: fears about law suits if a participant later develops a condition that could have been prevented.

- **Public trust in research**

- **Institution’s professional reputation**
Other arguments for an obligation to return genetic research results
Some arguments against an obligation to return incidental research findings

- Challenges to the notion that beneficence, respect for persons, reciprocity, justice are violated by lack of disclosure
- The purpose of research is not to benefit the individual research participant but rather to produce generalizable knowledge
- Risks associated with conflating research and clinical care
  - Therapeutic (diagnostic) misconception
- Resource limitations
What kind of genetic information generates an obligation?

- Some general agreement about the relevant factors:
  - Analytic validity
  - Clinical relevance
  - Actionable
  - Desired
But disagreements and controversial issues lurk:

- Why can’t we agree on a set of common definitions?
- How much does the research context matter?
- When is reconsent required?
- Do researchers have a duty to look for incidental findings?
- When is it appropriate to disclose genetic information to relatives of the proband?
- Is the right not to know absolute?
A Lack of Common Definitions

- “Clinical Significance”
  - Defining the threshold
    - Clear and immediate need vs. important health implication
    - Net benefit (strong, possible, unlikely)
    - Clinical utility, personal utility, general utility
    - Relative risk > X

- “Incidental”
  - Aims vs. methods

- “Actionable”
  - Reproductive information
  - Huntington’s Disease

- “Research Result”
  - Analytic validity - Is CLIA certification required?
Do All Studies Have to Return Incidental Findings

- Literature and guidelines have focused on defining the kind of information that might give rise to an obligation to return results.

- Emerging idea that the obligation to return incidental findings could also be a function of the research context:
  - Study characteristics
  - Population characteristics

Incorporating Factors Relating to the Research Characteristics

- **Nature of study**
  - Clinical trial, natural history, basic science

- **Study resources**
  - e.g., genetic counselors

- **Investigator expertise**

- **Specific aims**

- **Feasibility of recontact**
Incorporating Factors Relating to Subject Characteristics

- Alternative access/dependence
- Degree of vulnerability
- Depth of relationship
Case 1

A clinical researcher is studying the genetic etiology of breast cancer in a group of subjects that present for treatment at an academic medical center. After obtaining research-specific informed consent, the study team generates sequences data from surplus tumor tissue that had been removed for clinical purposes. They are interrogating the BRCA region to search for novel disease-associated variants. They propose to de-identify their sequence data, and do not plan to return any results. Although they are not searching for known disease-associated variants, it is likely that they will occasionally discover known BRCA variants that could be clinically relevant, particularly for near-term treatment decisions.
Facts

- The study was designed to examine the genetic basis of breast cancer subtypes in an understudied minority population.

- It represented a collaboration between X University and NIH researchers.

  - Clinical samples would be collected and at the extramural site, but would be sequenced and analyzed at NIH.
Facts

- The research team planned to de-identify the samples obtained.
- The relevant consent language read:
  - “Your name and anything else that could identify you will be removed and kept in a separate file. There will be a master list that links the code number to your name. This list will be stored on a secure computer with many levels of password protection.”
Facts

- The original research plans did not intend to inform prospective research participants of their individual research results.

- The relevant consent language read:
  - “You should not expect to get individual results from research done with your blood.”
Questions

- Would you approve this protocol as proposed? Why or why not?
- Is it relevant that the population being studied came from an underserved minority community that does not reliably have access to genetic testing?
Case 2

- A medical geneticist wants to add WES to his existing natural history study of a rare genetic disease. This would include analyzing specimens that were already collected under this protocol.

- Subjects enrolled in the study have ongoing contact with the research team, participating in quarterly follow-up visits and receiving standard of care treatment as needed.

- The original consent describes genetic analysis and a general plan not to return incidental findings unless clinically relevant to the management of the disease being investigated.
Questions

- Would you approve this amendment as proposed?
- Does it matter whether the investigator already has the infrastructure necessary to return genetic information to subjects?
Case 3

- A bench scientist studying a common, complex disorder wants to initiate a protocol to collect samples prospectively for WES.

- The protocol involves a one-time blood draw. Subjects will be recruited from sites across the country.

- There is no ongoing clinical relationship between researcher and subjects (but assume that recontact is feasible).

- The investigator does not have access to genetic counseling resources.
Questions

- Would you approve this protocol as proposed? Why or why not?
Case 4

- An NIH researcher has identified a source of clinical samples from patients at a biobank.
- The samples were collected with written informed consent and IRB approval.
- The samples will be coded, and the NIH researcher will not have access to any identifiable information about these patients.
- The NIH researcher wants to proceed with whole exome sequencing and set up a planning meeting with the sequencing center.
Question

Should investigators participating in biobank specimen research have an obligation to return incidental findings?
When is Reconsent Required?

A research study on genetic causes of asthma that incorporated targeted genetic tests was initiated several years ago. In the original consent, participants allowed “genetic analysis” of their samples, but next-generation sequencing (NGS) was not explicitly mentioned as it was not an option at the time. Now that NGS is less expensive, researchers would like to use it as part of their study to increase their chances of discovering genes related to asthma. They have submitted an amendment to the IRB describing the alternative sequencing plan, but this amendment does not explicitly mention a plan to obtain re-consent for NGS.
Questions

- Would you require these investigators to obtain reconsent?
- If the investigators make a good faith effort to recontact a participant, but fail to locate them, can their specimen be sequenced?
Re-examining the Stumble Strategy

- Assuming there is a duty to disclose significant incidental findings, might there be an obligation for researchers to actively look for these findings? (Gliwa and Berkman, forthcoming)

- Standard view: “researchers generally have no obligation to act as clinicians and affirmatively search for IFs,” (Wolf et al. 2008)
Questions

- Assuming that there is some obligation to return incidental findings that one stumbles upon, do investigators have a duty to look for incidental findings?

- What if a list of “reportable” variants existed
  - A committee-compiled and regularly-updated list of variants that meet a certain threshold of validity, severity, and actionability
Genomic Inheritances: Disclosing Individual Research Results From Whole-Exome Sequencing to Deceased Participants’ Relatives

Ben Chan, Lawrence University
Flavia M. Facio, National Human Genome Research Institute
Haley Eidem, National Human Genome Research Institute
Sara Chandros Hull, National Human Genome Research Institute
Leslie G. Biesecker, National Human Genome Research Institute
Benjamin E. Berkman, National Human Genome Research Institute

Whole-genome analysis and whole-exome analysis generate many more clinically actionable findings than traditional targeted genetic analysis. These findings may be relevant to research participants themselves as well as for members of their families. Though researchers performing genomic analyses are likely to find medically significant genetic variations for nearly every research participant, what they will find for any given participant is unpredictable. The ubiquity and diversity of these findings complicate questions about disclosing individual genetic test results. We outline an approach for disclosing a select range of genetic results to the relatives of research participants who have died, developed in response to relatives’ requests during a pilot study of large-scale medical genetic sequencing. We also argue that studies that disclose individual research results to participants should, at a minimum, passively disclose individual results to deceased participants’ relatives.

Keywords: genomics, medical genetics, research, genetic, personal genetic information, bioethical issues, ethics, research
Disclosure to Relatives

- Should genetic research results of potential clinical benefit be disclosed to a deceased participant’s relatives?
- If so, under what circumstances and through what mechanism should they be disclosed?
- What subset of the results should be disclosed?
The Right Not to Know

GENOME PROJECT

WHEN I ASKED WHAT LITTLE GIRLS ARE MADE OF, I WAS HOPING HE WOULD SAY "SUGAR AND SPICE."
One Area of Apparent Consensus

- Findings should only be returned when they are desired by the research participant
- An obligation to *offer* individual findings to research subjects
- Discuss right not to know and solicit subject preferences
  - IFs should only be *offered* when “During the informed consent process or subsequently, the study participant has opted to receive his or her individual genetic results.”
Standard Ethical Review

- If a participant has asserted a desire not to know and such consent is valid, standard ethical analysis suggests that such results must not be returned
  - Autonomy
  - Privacy
- Extensive support in the genetic testing and research ethics literature
  - E.g., BRCA, Huntington’s, Alzheimer’s
  - Incidental findings guidance documents
Questions

- Are traditional conceptions about the “right not to know” appropriate in a genomic research context?
- How should a subject’s desire not to know genetic information be solicited?
- Are there any (limited) circumstances where it might be ethically appropriate to override an individual’s expressed wish not to know genetic information about themselves?
Case

A participant has chosen on the consent form not to receive any GIF results. During its analysis, the research team finds evidence of high genetic risk for Hereditary Non-Polyposis Colon Cancer (HNPCC). The team believes this information will prevent serious disease and perhaps even save the life of the participant. The team should disclose the finding, even though the participant indicated that he/she did not want to receive any GIFs.
Thank you

- **Acknowledgements**
  - Sara Hull

- **Questions:**
  - berkmanbe@mail.nih.gov